Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...
Q3 2025 Earnings Call October 23, 2025 4:30 PM EDTCompany ParticipantsLuke NicholsMark George - President, CEO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback